Newer Treatment Strategies for the Management of Type 2 Diabetes Mellitus

Journal of Pharmacy Practice

Volumn 17, Issue 1, 2004, Pages 49-54

  Cornell, Susan ^a,b,c   Briggs, Amber ^b,d  

^a Chicago College of Pharmacy ^*  (United States)

^b MIDWESTERN UNIVERSITY   (United States)

^c Dominick's Pharmacy   (United States)

^d Dominick's Pharmacy   (United States)

Author keywords

A1C; Algorithm; Nonpharmacological; Pharmacological; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; HEMOGLOBIN A1C; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MIGLITOL; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA;

ALGORITHM; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CARDIOVASCULAR RISK; DIARRHEA; DIET THERAPY; EDEMA; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; METABOLIC DISORDER; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT EDUCATION; PHYSICAL ACTIVITY; REVIEW; RISK FACTOR; SIDE EFFECT; VASCULAR DISEASE; WEIGHT GAIN;

EID: 1642457304     PISSN: 08971900     EISSN: None     Source Type: Journal    
DOI: 10.1177/0897190003261308     Document Type: Review

References (24)

1. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care. 2000;23:1278-1283.
2. Diabetes Research Working Group. Summary of the report and recommendations of the congressionally-established Diabetes Research Working Group: a strategic plan for the 21st century. 1999. Retrieved September 10, 2003, from http://www.jdfcure.org/drwg/.
3. Mitzner L. Selecting the best medication for type 2 diabetes. Cortlandt Forum. 2003;16(8):16-19.
4. Weyer C, Bogardus C, Mott D, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest. 1999;104(6):787-794.
5. Wyne KL. The need for reappraisal of type 2 diabetes mellitus management Postgrad Med. 2003;8:5-14.
6. Anderson RM, Funnell MM. The Art of Empowerment: Stories and Strategies for Diabetes Educators. Alexandria, VA: American Diabetes Association; 2000.
7. Reddan LP, et al. Nutrition, obesity and exercise. In: Lifescan Diabetes Programs. Pharmacy Partners in Diabetes Care. 2nd ed. Philadelphia, Pa: CoMed Communications, Inc; 2000:2-18.
8. Franz MJ, Kulkarni K, Daly AS, et al. Therapies: nutrition. In: A Core Curriculum for Diabetes Education. 3rd ed. Chicago, Ill: American Association of Diabetes Educators; 1998:189-256.
9. Peragallo-Dittko V. Therapies: monitoring. In: A Core Curriculum for Diabetes Education. 3rd ed. Chicago, Ill: American Association of Diabetes Educators; 1998:361-383.
10. Kistler JA. Therapies: exercise. In: A Core Curriculum for Diabetes Education. 3rd ed. Chicago, Ill: American Association of Diabetes Educators; 1998:257-296.
11. Nomura DM. Issues in monitoring. In: Lifescan Diabetes Programs. Pharmacy Partners in Diabetes Care. 2nd ed. Philadelphia, Pa: CoMed Communications, Inc; 2000:2-18.
12. Bell DS. Beneficial effects resulting from thiazolidinediones for treatment of type 2 diabetes mellitus. Postgrad Med. 2003;8:35-44.
13. Luna B, Feinglos MN. Oral agents in the management of type 2 diabetes mellitus. Am Fam Physician. 2001;63(9):1747-1756.
14. Nomura DM. Understanding diabetes: classification, pathophysiology and status of intervention studies. In: Lifescan Diabetes Programs. Pharmacy Partners in Diabetes Care. 2nd ed. Philadelphia, Pa: CoMed Communications, Inc; 2000:2-53.
15. Talbert RL. Hyperlipidemia. In: Dipiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A Pathophysiologic Approach. 4th ed. Stamford, CT: Appleton & Lange; 1999:350-373.
16. Luscher TF. Endothelial dysfunction in atherosclerosis. J Myocardial Ischemia. 1995;7(supp 1):15-20.
17. Braunstein S. Cardiovascular disease and benefits of thiazolidinediones. Postgrad Med. 2003;8:45-52.
18. Eckel RH. Perspectives on vascular biology and diabetes. J Invest Med. 2001;1(supp 1):100-103.
19. Prescott SM, McIntyre TM, Zimmerman GA. Events at the vascular wall: the molecular basis of inflammation. J Invest Med. 2001;1(supp 1):104-111.
20. Hsueh WA. PPAR-gamma effects on the vasculature. J Invest Med. 2001;1(supp 1):127-129.
21. Zettervall DK. Oral diabetes agents: In: Lifescan Diabetes Programs. Pharmacy Partners in Diabetes Care. 2nd ed. Philadelphia, Pa: CoMed Communications, Inc; 2000.
22. Wyne KL, Drexler AJ, Miller JL, et al. Constructing an algorithm for managing type 2 diabetes: focus on the role of the thiazolidinediones. Postgrad Med. 2003;8:63-72.
23. Bell DS, Leahy JL, Piziak VK. Achieving glycemic control with insulin in type 2 diabetes. Patient Care. 2002;10:59-84.
24. Mudaliar S, Edelman SV. Insulin therapy in type 2 diabetes. Endocrinol Metab Clin North Am. 2001;30:935-982.